الريادة في طب جمالي أكثر أمانًا وتقدّمًا

Hero background

وتقدّمًافي طليعة الابتكار منذ عام 2003


 

نحتفل بمحطّاتنا البارزة في مجال الطب الجمالي، حيث تُجسّد مسيرتنا التزام تيوكسان بتطوير هذا القطاع وتعزيز السلامة من خلال التميّز السريري والتعليم الطبي. اكتشف كيف ساهمت جهودنا المستمرة في دفع عجلة التطوّر في هذا المجال لخدمة المرضى والممارسين على حدٍّ سواء.

تابِعونا على قنواتنا
  • Instagram
  • LinkedIn
  • Facebook
  • YouTube
تواصلوا معنا

هل تواجه مشكلة؟
نحن هنا لمساعدتك.

  • © 2025 Teoxane

TEOXANE Cosmeceuticals range are cosmetic product according to European Regulation 1223/2009. Excepted Radiant Night Peel which is a medical device, class I, according to Directive 93/42/EEC. Cosmeceuticals products are not designed to be injected.

*(depending on country registration)
**at Teoxane Laboratories **Redensity 2 = TEOSYAL® PureSense Redensity 2

Medical devices for professional use only. Product indications and availability vary from country to country. Please consult product instructions locally approved for more information. Contact for materiovigilance notification: medical@teoxane.com
 

1. The TEOXANE cosmetics comply with the requirements of the European regulation 1223/2009. Cosmetic products are not designed to be injected.
2. TEOSYAL® PureSense Redensity 2 –Instructions for use. 
3. Berguiga M, Galatoire O. Tear trough rejuvenation: a safety evaluation of the treatment by a semi-crosslinked Hyaluronic Acid Filler.  Orbit, 2017; 36 (1):22-26. 
4. Anido et al. J: Recommendations for the treatment of tear trough deformity with cross-linked hyaluronic acid filler, Cosmet Dermatol 2020;00:1–12
5. Fanian et al, «In-vivo injection of oligonutrients and high molecular weight hyaluronic acid -results of a randomized controlled trial,» Aesthetic medicine-official journal of the international union of aesthetic medicine UIME, 2017.
6. Rzany B, Converset-Viethel S, Hartmann M, et al. Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles: Results of an 18-Month, Randomized Controlled Trial Versus Already Available Comparators. Dermatol Surg. 2019;45(10):1304-1314.
7. FDA Executive Summary General Issues Panel Meeting on Dermal Fillers - March 23, 2021
8. Teoxane internal data source. TEOSYAL® PureSense Redensity 2 deliveries from 2012 to 2022 (Jan-Aug) : 3’262’520 syringes